IM19 chimeric antigen receptor T cell therapy - Beijing Immunochina Medical Science and Technology
Alternative Names: IM19 CAR-T cells; IM19-CAR-T-Cells-Beijing-Immunochina-Medical-Science-and-Technology; IM19CAR-T; IM19CAR-T-Beijing-Immunochina-Medical-Science-and-TechnologyLatest Information Update: 22 Nov 2024
At a glance
- Originator Beijing Immunochina Medical Science and Technology
- Developer Beijing Immunochina Medical Science and Technology; Peking University Third Hospital
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Diffuse large B cell lymphoma; Leukaemia
- Phase I/II Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Phase I Precursor B-cell lymphoblastic leukaemia-lymphoma
- Clinical Phase Unknown Systemic lupus erythematosus
Most Recent Events
- 04 Nov 2024 Beijing Immunochina Medical Science & Technology plans an early phase I trial for IgA nephropathy in November 2024 (NCT06690359)
- 30 Jul 2024 Clinical trials in Systemic lupus erythematosus in China (IV) (NCT06513429)
- 09 Dec 2023 Phase-I/II clinical trials in Mantle-cell lymphoma (Second-line therapy or greater) (Parenteral) before December 2023 (NCT05155215)